Abstract: Disclosed is a method of manufacturing a polyurethane filter foam having excellent air permeability, elasticity, and restoring force. In the method of manufacturing the polyurethane filter foam, the cell size of the filter foam is made regular by controlling the pressure by adjusting the diameter of the foaming head of a foaming machine, rather than adding a cell opener, cell irregularity caused by poor dispersion of the cell opener is alleviated, and air permeability, porosity, and compression set are excellent.

Abstract: A display device includes: a first display area including a plurality of data lines extending in a first direction; a second display area at one side of the first display area, comprising a plurality of data lines shorter than the data lines of the first display area; a first non-display area adjacent to the first display area; and a second non-display area adjacent to the second display area, comprising a plurality of load matching units respectively connected to the plurality of data lines of the second display area and configured to compensate for load capacitance of the plurality of data lines of the second display area.

Abstract: Provided is a light emitting display device comprising a driving transistor; a second transistor; a light emitting diode; a storage capacitor; a first scan line; and a driving gate electrode, in which a pixel includes only a transistor including an oxide semiconductor. The light emitting display device prevents deterioration of display quality due to a boost capacitor with a scan line in a pixel using an n-type transistor including an oxide semiconductor. Further, the light emitting display device prevents deterioration of display quality due to coupling with a data line in a pixel using an n-type transistor.

Abstract: The invention provides compounds of formulae A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: Discussed is a display device including a display panel, first gate lines located on the display panel, second gate lines separated from the first gate lines and located on the display panel, first data lines provided on the display panel corresponding to a first display area to cross the first gate lines and defining first pixel areas configuring the first display area, second data lines provided on the display panel corresponding to a second display area to cross the second gate lines and second pixel areas configuring the second display area, wherein the first pixel areas and the second pixel areas have the same size, and wherein a separation area is interposed between the first gate lines and the second gate lines, and a width of the separation area is equal to or wider than a width of a thin film transistor.

Abstract: A user wears a virtual reality mask (VR mask) (100) and then watches a virtual reality image. The VR mask (100) blocks light incident from the outside. When the user wears the VR mask (100), the user cannot discover an obstacle (500) positioned outside the VR mask (100). The user may collide with the obstacle (500) and may be injured by the obstacle (500). Accordingly, in order to prevent injury to the user who uses the VR mask (100), it is necessary to make the user recognize the obstacle (500) positioned outside the VR mask (100). In order to recognize an obstacle, a virtual reality image and the obstacle may be displayed together, or the amount of light incident from the outside may be adjusted.

Abstract: A user wears a virtual reality mask (VR mask) (100) and then watches a virtual reality image. The VR mask (100) blocks light incident from the outside. When the user wears the VR mask (100), the user cannot discover an obstacle (500) positioned outside the VR mask (100). The user may collide with the obstacle (500) and may be injured by the obstacle (500). Accordingly, in order to prevent injury to the user who uses the VR mask (100), it is necessary to make the user recognize the obstacle (500) positioned outside the VR mask (100). In order to recognize an obstacle, a virtual reality image and the obstacle may be displayed together, or the amount of light incident from the outside may be adjusted.

Abstract: The invention provides compounds of formulae A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: Discussed is a display device including a display panel, first gate lines located on the display panel, second gate lines separated from the first gate lines and located on the display panel, first data lines provided on the display panel corresponding to a first display area to cross the first gate lines and defining first pixel areas configuring the first display area, second data lines provided on the display panel corresponding to a second display area to cross the second gate lines and second pixel areas configuring the second display area, wherein the first pixel areas and the second pixel areas have the same size, and wherein a separation area is interposed between the first gate lines and the second gate lines, and a width of the separation area is equal to or wider than a width of a thin film transistor.

Abstract: A display device in one embodiment includes a display panel configured to display an image in first and second display areas, a plurality of first gate lines corresponding to the first display area, and a plurality of second gate lines separated from the first gate lines and corresponding to the second display area. Accordingly, the distance between the first gate lines of the first display area and the second gate lines of the second display area is maximized to prevent static electricity from occurring between the electrodes, thereby increasing product yield.

Abstract: The invention provides heterocyclic compounds of formula A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: We describe the use of comparative structural analysis and structure-guided molecular design to develop potent and selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13). We applied a three-step process, starting with a comparative analysis of the X-ray crystallographic structure of compound 5 in complex with MMP-13 with published structures of known MMP-13 inhibitor complexes followed by molecular design and synthesis of potent, but non-selective zinc-chelating MMP inhibitors (e.g., 10a and 10b). After demonstrating that the pharmacophores of the chelating inhibitors (S)-10a, (R)-10a, and 10b were binding within the MMP-13 active site, the Zn2+ chelating unit was replaced with non-chelating polar residues that bridged over the Zn2+ binding site and reach into a solvent accessible area.

Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: A display device in one embodiment includes a display panel configured to display an image in first and second display areas, a plurality of first gate lines corresponding to the first display area, and a plurality of second gate lines separated from the first gate lines and corresponding to the second display area. Accordingly, the distance between the first gate lines of the first display area and the second gate lines of the second display area is maximized to prevent static electricity from occurring between the electrodes, thereby increasing product yield.

Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: A user interface method for a terminal for a vehicle is provided. The terminal obtains position information to detect a point of a road. A road image of a driving direction is obtained, a lanes of the road represented on the obtained road image is recognized, and a point of a road and lane in which the vehicle having the terminal arranged therein is detected. A virtual road image regarding the recognized lanes is generated, and the generated virtual lanes are added to the road image of the driving direction of the vehicle, and displayed. Traffic information for each lane and surrounding information (i.e. lane closure, construction, accident, etc.,) at the detected point of the relevant road are obtained, and the obtained information is displayed for each virtual lane.

Abstract: A user interface method for a terminal for a vehicle is provided. The terminal obtains position information to detect a point of a road. A road image of a driving direction is obtained, a lanes of the road represented on the obtained road image is recognized, and a point of a road and lane in which the vehicle having the terminal arranged therein is detected. A virtual road image regarding the recognized lanes is generated, and the generated virtual lanes are added to the road image of the driving direction of the vehicle, and displayed. Traffic information for each lane and surrounding information (i.e. lane closure, construction, accident, etc.,) at the detected point of the relevant road are obtained, and the obtained information is displayed for each virtual lane.

Abstract: A user interface method for a terminal for a vehicle is provided. The terminal obtains position information to detect a point of a road. A road image of a driving direction is obtained, a lanes of the road represented on the obtained road image is recognized, and a point of a road and lane in which the vehicle having the terminal arranged therein is detected. A virtual road image regarding the recognized lanes is generated, and the generated virtual lanes are added to the road image of the driving direction of the vehicle, and displayed. Traffic information for each lane and surrounding information (i.e. lane closure, construction, accident, etc.,) at the detected point of the relevant road are obtained, and the obtained information is displayed for each virtual lane.

Abstract: A method and an apparatus for setting a navigation screen update cycle in a mobile terminal are provided. In the method, at least one of a velocity of the mobile terminal and a map scale used by the mobile terminal is obtained. A screen update cycle is set with consideration of the at least one of the velocity and the map scale. A navigation screen display is updated according to the set screen update cycle.